Arsenic Trioxide (Trisenox®) Therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem Cell Transplantation

• Published in: The oncologist (Dayton, Ohio) Ohio), 2003-04, Vol.8 (2), p.132-140
• Main Authors: Douer, Dan, Hu, Wendy, Giralt, Sergio, Lill, Michael, DiPersio, John
• Format: Article
• Language: English
• Subjects: Acute promyelocytic leukemia; Antineoplastic Agents - standards; Antineoplastic Agents - therapeutic use; Arsenic Trioxide; Arsenicals - standards; Arsenicals - therapeutic use; Clinical Trials as Topic; Combined Modality Therapy; Europe; Hematopoietic Stem Cell Transplantation - standards; Humans; Leukemia, Promyelocytic, Acute - epidemiology; Leukemia, Promyelocytic, Acute - therapy; Molecular remission; Neoplasm Regression, Spontaneous; Oxides - standards; Oxides - therapeutic use; Practice Guidelines as Topic; Risk Factors; Transplantation; Tretinoin - standards; Tretinoin - therapeutic use; United States - epidemiology
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.8-2-132

Learning Objectives After completing this course, the reader will be able to: Explain how to treat patients with relapsed acute promyelocytic leukemia. Describe how to use arsenic trioxide in acute promyelocytic leukemia and be familiar with drug's side effects. Identify the role of bone marrow transplantation in acute promyelocytic leukemia. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at.CME.TheOncologist.com The relapse‐free survival of patients with acute promyelocytic leukemia (APL) has significantly increased during the last decade. The introduction of all‐trans retinoic acid (ATRA) doubled the survival of patients with this disease. However, despite ATRA and anthracycline‐based chemotherapy, 12%–30% of patients will still relapse. Arsenic trioxide (ATO) has demonstrated efficacy and safety in patients with first and subsequent relapsed or refractory APL, regardless of the disease‐free interval. Treatment of relapsed and refractory patients with this novel therapy produces complete remission in 87% of patients and molecular remission in 83%. Studies have documented the efficacy of autologous and allogeneic transplantation as salvage therapy in relapsed and refractory APL. The introduction of ATO into the treatment regimen for APL has stimulated discussion on its role in the transplantation setting. Investigators recently met to discuss the issue and make recommendations regarding ATO therapy in patients who are in their second or subsequent complete remission and are candidates for transplantation. This article describes the pivotal studies of this novel agent, discusses risk factor stratification for relapse in patients with APL, and proposes protocols for treatment incorporating ATO therapy. In addition, it describes scientific issues in ongoing and proposed clinical trials of ATO therapy for this disease.